Internal medicine

American College of Physicians issues clinical recommendations for newer pharmacological treatments of adults with Type 2 diabetes

Retrieved on: 
Friday, April 19, 2024
ACP, Mortality, MACP, Stroke, Annals of Internal Medicine, American College, Meta-analysis, Risk, DPP-4, Guideline, Development, Assessment, Type 2 diabetes, Type 2, GRADE, Patient, Diabetes, Myocardial infarction, Weight loss, Internal medicine, Hospital, Chronic kidney disease, Metformin, Hypoglycemia, Heart, Systematic review, Disease

BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs. Newer Pharmacological Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians was published today in Annals of Internal Medicine.

Key Points: 
  • Reviews evidence of newer medications, recommends adding to metformin
    BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes.
  • Newer Pharmacological Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians was published today in Annals of Internal Medicine.
  • ACP today released clinical recommendations for the use of newer treatments in adults with Type 2 diabetes.
  • This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacological treatments for Type 2 diabetes.

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

Retrieved on: 
Tuesday, April 16, 2024
FDA, CMO, Psychiatry, SPA, Internal medicine, Therapy, Science, GSK, Patient, Neurology, ALS, Medicine, Drug development, Medical Center, Pharmaceutical industry

NEW YORK, April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prepares to embark on a registrational Phase 3b trial for NurOwn®, its investigational cell therapy treatment for amyotrophic lateral sclerosis (ALS).

Key Points: 
  • These strategic management changes are being made as the Company prepares to embark on a registrational Phase 3b trial for NurOwn®, its investigational cell therapy treatment for amyotrophic lateral sclerosis (ALS).
  • In his new role as Executive Vice President and Chief Medical Officer, Dr. Dagher's responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn.
  • "Bob's capabilities, which include expertise in neurology, psychiatry, and rare diseases, make him exceptionally qualified as we launch the Phase 3b trial of NurOwn and prepare for success.
  • The opportunity to lead our talented clinical team through the upcoming Phase 3b trial is incredibly exciting.

The Inner Circle acknowledges Tanveer P. Mir, MD, MACP as a Pinnacle Lifetime Member

Retrieved on: 
Friday, April 12, 2024
Organization, Administration, MACP, American College, Palliative care, MBBS, Hospice, Gardening, Health, Internal medicine, Geriatrics, Mentorship, GLEN, Parent, North Shore University Hospital, Bachelor, Patient, Teaching hospital, Multimedia, Nassau University Medical Center, Inner circle, Knowledge, Nursing

GLEN COVE, N.Y., April 12, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Tanveer P. Mir, MD, MACP is acknowledged as a Pinnacle Lifetime Member for her contributions as a Respected Leader in Medicine and Administration.

Key Points: 
  • GLEN COVE, N.Y., April 12, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Tanveer P. Mir, MD, MACP is acknowledged as a Pinnacle Lifetime Member for her contributions as a Respected Leader in Medicine and Administration.
  • Her dedication to patient care and her leadership in healthcare institutions have solidified her reputation as a respected figure in the industry.
  • Currently serving as the Chairperson at NYC Health + Hospitals/South Brooklyn Health, Ruth Bader Ginsburg Hospital, Dr. Mir oversees various administrative functions of the facility.
  • She is deeply committed to providing the highest quality of care to the elderly population, addressing their unique healthcare needs.

Is Universal Healthcare A Solution to U.S. Healthcare Disparities? The Binaytara Foundation Hosts a Debate on this Crucial Topic with Global Leaders

Retrieved on: 
Thursday, April 11, 2024
Health equity, Hematology, University of California, Doctor of Philosophy, Health, Senate, Legislation, Private sector, Associate, Duke University, Bone marrow, Physician, Summit, American Medical Association, American Cancer Society, Transport, Justice Select Committee, ACS, Binaytara Foundation, Master of Science, MPH, Consultant, Organization, University, Cancer, American College, Way, Policy, Health care, Deportation, Plague, Patient, MBA, Internal medicine, FACP

BELLEVUE, Wash., April 11, 2024 /PRNewswire-PRWeb/ -- The Binaytara Foundation, a leading non-profit organization dedicated to promoting health equity and addressing healthcare disparities, is pleased to announce an upcoming debate on the topic: "Is Universal Healthcare A Solution to U.S. Healthcare Disparities?" The debate will be held April 28, during The Summit on Cancer Health Disparities (SCHD24), which will take place in Seattle from April 26 to 28, 2024.

Key Points: 
  • Healthcare disparities continue to plague communities across the United States, and the globe disproportionately affecting marginalized and underserved populations.
  • As the nation grapples with how to address these disparities, the debate on the efficacy of universal healthcare has taken center stage.
  • The Binaytara Foundation recognizes the importance of engaging in thoughtful discourse on this critical issue and is bringing together global leaders, healthcare experts, policymakers, and advocates to explore the potential of universal healthcare in addressing healthcare disparities in the United States at its summit.
  • How might universal healthcare affect medical innovation and the development of new treatments and technologies in the U.S. healthcare system?

MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner

Retrieved on: 
Thursday, April 11, 2024
University, Kite, Sanofi, Research, MD Anderson Cancer Center, MPM, History, Takeda Pharmaceutical Company, Heinrich Heine University Düsseldorf, Senior, Patient, Intellectual property, Internal medicine, Biotechnology, AstraZeneca, Verastem Oncology, Bluebird bio, Nursing

In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.

Key Points: 
  • In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.
  • "Frank is an innovator and distinguished leader with a demonstrated history of success in CAR-based cell therapy and clinical advancement," said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact.
  • Dr. Neumann's deep clinical experience will serve to support MPM BioImpact's investment process and the advancement of its underlying portfolio companies.
  • "I'm thrilled to join the MPM BioImpact ecosystem and contribute to its patient-focused mission," said Dr. Neumann.

Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 11, 2024
University, Sanofi, RNA, Research, MD Anderson Cancer Center, MPM, Takeda Pharmaceutical Company, Heinrich Heine University Düsseldorf, Therapy, Bone marrow, Partner (business rank), Senior, Patient, Internal medicine, Biotechnology, AstraZeneca, Verastem Oncology, Bluebird bio

WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer. In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.

Key Points: 
  • WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.
  • In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.
  • "We are delighted to welcome Frank, an accomplished leader with a proven track record in CAR-based cell therapy and clinical development," said Tom Barnes, Ph.D., Chief Executive Officer of Orna Therapeutics.
  • "Orna's truly innovative approach to RNA therapeutics shows incredible promise to fundamentally change the way life-threatening diseases are treated," said Dr. Neumann.

Concierge Choice Physicians Hosts "Embrace Challenges and Change with Informed Choices: A Symposium on Concierge Medicine in Healthcare Organizations"

Retrieved on: 
Wednesday, April 10, 2024
Weill Cornell Medicine, Patient, Concierge medicine, Primary care, CCP, Nassau Street, Concierge, MD, Dean (education), MPH, Medicine, Internal medicine, Recruit, FACP, Organization, Health, Hospital

ROCKVILLE CENTRE, N.Y., April 10, 2024 /PRNewswire/ -- Concierge Choice Physicians (CCP), the nation's leading full-service concierge medical service provider, announces a special event for healthcare executives titled "Embrace Challenges and Change with Informed Choices: A Symposium on Concierge Medicine in Healthcare Organizations" to be held on Thursday, May 16, 2024 at The Beekman Hotel, 123 Nassau Street, New York, NY 10038.

Key Points: 
  • This unique, one-day event will feature executives from several large medical groups and hospital systems discussing their experience with CCP's membership medicine programs in a series of small, interactive roundtable discussions.
  • Concierge Choice Physicians' flexible and blended approach to membership medicine has driven a lot of that change.
  • "Large medical groups and hospital systems are now our fastest growing market," says Keith Elgart, Chief Operating Officer at Concierge Choice Physicians.
  • Registration information for the complimentary event, "Embrace Challenges and Change with Informed Choices: A Symposium on Concierge Medicine in Healthcare Organizations," is available at www.ccpmd.com/roundtable , or call 877.888.5590 or email [email protected] to learn more.

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Internal medicine, Onyx Pharmaceuticals, Immunotherapy, Hematology, Science, University, Biology, MBA, University of California, Therapy, Division, Eli Lilly and Company, CMO, University of Southern California, Pharmaceutical industry

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.

Key Points: 
  • BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.
  • Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.
  • She currently serves on the Board of Directors of Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. She is also a scientific advisor to several clinical-stage oncology and immunotherapy companies.
  • “I am honored to transition from my role as a scientific advisor to a member of the Board of Directors,” said Dr. Kunkel.

NBME Recognizes Dr. Karen Hauer with Prestigious Medical Education Research Award

Retrieved on: 
Tuesday, April 2, 2024
Medical education, Internal medicine, Education, UCSF, Communication, Learning, Science, International, Patient, Bias, Knowledge, Research, University, Doctor of Philosophy, Faculty, MD, Student, Thought, MBA, UCSF Medical Center, Habit, Stanford University, Feedback, Physician, Health, NBME, Nursing

PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Karen Hauer, MD, PhD, was selected as the recipient of NBME’s 2024 John P. Hubbard Award in recognition of her significant contributions to the field of medical education research and assessment.

Key Points: 
  • PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Karen Hauer, MD, PhD, was selected as the recipient of NBME’s 2024 John P. Hubbard Award in recognition of her significant contributions to the field of medical education research and assessment.
  • NBME President and CEO Peter Katsufrakis, MD, MBA, echoes her sentiments about past Hubbard Award recipients and expresses his support and admiration for Dr. Hauer and her accomplishments.
  • She is an active researcher in health professions education with a focus on competency-based medical education, workplace-based assessment, equity and coaching.
  • P. Hubbard Award recognizes individuals for their outstanding contributions to the pursuit of assessment excellence within medical education.

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO

Retrieved on: 
Tuesday, April 2, 2024
Lung cancer, Internal medicine, Stanford Cancer Institute, Entrepreneurship, Princeton University, Immunotherapy, Oncology, International Association, Research, Cancer, Doctor of Philosophy, MD, Mesothelioma, CD24, MacArthur Fellows Program, Johns Hopkins University, Principal investigator, SAB, Division, Stanford University, CSO, Thymoma, Pharmaceutical industry

“We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.

Key Points: 
  • “We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.
  • By leveraging universal pathways, OncoC4 has the potential to change the treatment paradigm for many common and aggressive cancers with high unmet needs.
  • Currently she serves as Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology.
  • She is the Principal Investigator on numerous clinical trials and has held advisory board roles with multiple international pharmaceutical companies.